Fenofibrate and extended-release niacin improve the endothelial protective effects of HDL in patients with metabolic syndrome

Vascular Pharmacology

Volumn 74, Issue , 2015, Pages 80-86

  Gomaraschi, Monica ^a   Ossoli, Alice ^a   Adorni, Maria Pia ^b   Damonte, Elisabetta ^c   Niesor, Eric ^c   Veglia, Fabrizio ^d   Franceschini, Guido ^a   Benghozi, Renee ^c   Calabresi, Laura ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d CENTRO CARDIOLOGICO MONZINO   (Italy)

Author keywords

Endothelial cells; Fenofibrate; High density lipoprotein; Niacin; Nitric oxide

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; ANTILIPEMIC AGENT; DELAYED RELEASE FORMULATION; NOS3 PROTEIN, HUMAN; PROTECTIVE AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG RELEASE; DYSLIPIDEMIA; ENDOTHELIUM CELL; FEMALE; HOMEOSTASIS; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; TREATMENT DURATION; UMBILICAL VEIN ENDOTHELIAL CELL; BLOOD; CELL CULTURE; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DRUG EFFECTS; METABOLISM; MIDDLE AGED; THERAPEUTIC USE;

CELLS, CULTURED; CHOLESTEROL, HDL; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; ENDOTHELIAL CELLS; FEMALE; FENOFIBRATE; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NIACIN; NITRIC OXIDE SYNTHASE TYPE III; PROTECTIVE AGENTS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84947614681     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2015.06.014     Document Type: Article

References (52)

1. Castelli W.P., Anderson K.M., Wilson P.W., Levy D. Lipids and risk of coronary heart disease. The Framingham Study. Ann. Epidemiol. 1992, 2:23-28.
2. Di Angelantonio E., Sarwar N., Perry P., Kaptoge S., Ray K.K., Thompson A., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302:1993-2000.
3. Cuchel M., Rader D.J. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis?. Circulation 2006, 113:2548-2555.
4. Calabresi L., Gomaraschi M., Franceschini G. Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1724-1731.
5. Cockerill G.W., Rye K.A., Gamble J.R., Vadas M.A., Barter P.J. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol. 1995, 15:1987-1994.
6. Yuhanna I.S., Zhu Y., Cox B.E., Hahner L.D., Osborne-Lawrence S., Lu P., et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat. Med. 2001, 7:853-857.
7. Chapman M.J. Beyond the statins: new therapeutic perspectives in cardiovascular disease prevention. Cardiovasc. Drugs Ther. 2005, 19:135-139.
8. Barter P.J., Rye K.A. Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. J. Lipid Res. 2012, 53:1755-1766.
9. Chapman M.J., Redfern J.S., McGovern M.E., Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol. Ther. 2010, 126:314-345.
10. Gomaraschi M., Adorni M.P., Banach M., Bernini F., Franceschini G., Calabresi L. Effects of established hypolipidemic drugs on HDL concentration, subclass distribution, and function. Handb. Exp. Pharmacol. 2015, 224:593-615.
11. The FIELD study investigators Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861.
12. Ginsberg H.N., Elam M.B., Lovato L.C., Crouse J.R., Leiter L.A., Linz P., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 2010, 362:1563-1574.
13. Boden W.E., Probstfield J.L., Anderson T., Chaitman B.R., svignes-Nickens P., Koprowicz K., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 2011, 365:2255-2267.
14. HPS2-THRIVE Collaborative Group HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur. Heart J. 2013, 34:1279-1291.
15. deGoma E.M., deGoma R.L., Rader D.J. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J. Am. Coll. Cardiol. 2008, 51:2199-2211.
16. Calabresi L., Gomaraschi M., Franceschini G. High-density lipoprotein quantity or quality for cardiovascular prevention?. Curr. Pharm. Des. 2010, 16:1494-1503.
17. Franceschini G., Favari E., Calabresi L., Simonelli S., Bondioli A., Adorni M.P., et al. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients. J. Clin. Lipidol. 2013, 7:414-422.
18. Demacker P.N., Veerkamp M.J., Bredie S.J., Marcovina S.M., de Graaf J., Stalenhoef A.F. Comparison of the measurement of lipids and lipoproteins versus assay of apolipoprotein B for estimation of coronary heart disease risk: a study in familial combined hyperlipidemia. Atherosclerosis 2000, 153:483-490.
19. Otvos J.D., Jeyarajah E.J., Bennett D.W., Krauss R.M. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin. Chem. 1992, 38:1632-1638.
20. Murakami T., Michelagnoli S., Longhi R., Gianfranceschi G., Pazzucconi F., Calabresi L., et al. Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling in human plasma. Arterioscler. Thromb. Vasc. Biol. 1995, 15:1819-1828.
21. Calabresi L., Nilsson P., Pinotti E., Gomaraschi M., Favari E., Adorni M.P., et al. A novel homozygous mutation in CETP gene as a cause of CETP deficiency in a Caucasian kindred. Atherosclerosis 2009, 205:506-511.
22. Calabresi L., Pisciotta L., Costantin A., Frigerio I., Eberini I., Alessandrini P., et al. The molecular basis of lecithin:cholesterol acyltransferase deficiency syndromes: a comprehensive study of molecular and biochemical findings in 13 unrelated Italian families. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1972-1978.
23. Calabresi L., Favari E., Moleri E., Adorni M.P., Pedrelli M., Costa S., et al. Functional LCAT is not required for macrophage cholesterol efflux to human serum. Atherosclerosis 2009, 204:141-146.
24. Gomaraschi M., Baldassarre D., Amato M., Eligini S., Conca P., Sirtori C.R., et al. Normal vascular function despite low levels of high-density lipoprotein cholesterol in carriers of the apolipoprotein A-I(Milano) mutant. Circulation 2007, 116:2165-2172.
25. Gomaraschi M., Ossoli A., Favari E., Adorni M.P., Sinagra G., Cattin L., et al. Inflammation impairs eNOS activation by HDL in patients with acute coronary syndrome. Cardiovasc. Res. 2013, 100:36-43.
26. Grizzle J.E. The two-period change-over design and its use in clinical trials. Biometrics 1965, 21:467-480.
27. Mineo C., Deguchi H., Griffin J.H., Shaul P.W. Endothelial and antithrombotic actions of HDL. Circ. Res. 2006, 98:1352-1364.
28. Besler C., Heinrich K., Rohrer L., Doerries C., Riwanto M., Shih D.M., et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J. Clin. Invest. 2011, 121:2693-2708.
29. Sorrentino S.A., Besler C., Rohrer L., Meyer M., Heinrich K., Bahlmann F.H., et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 2010, 121:110-122.
30. Speer T., Rohrer L., Blyszczuk P., Shroff R., Kuschnerus K., Krankel N., et al. Abnormal high-density lipoprotein induces endothelial dysfunction via activation of toll-like receptor-2. Immunity 2013, 38:754-768.
31. Mineo C., Yuhanna I.S., Quon M.J., Shaul P.W. High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J. Biol. Chem. 2003, 278:9142-9149.
32. De Beer M.C., Durbin D.M., Cai L., Mirocha N., Jonas A., Webb N.R., et al. Apolipoprotein A-II modulates the binding and selective lipid uptake of reconstituted high density lipoprotein by scavenger receptor BI. J. Biol. Chem. 2001, 276:15832-15839.
33. Rinninger F., Brundert M., Budzinski R.M., Fruchart J.C., Greten H., Castro G.R. Scavenger receptor BI (SR-BI) mediates a higher selective cholesteryl ester uptake from LpA-I compared with LpA-I:A-II lipoprotein particles. Atherosclerosis 2003, 166:31-40.
34. Martinelli N., Micaglio R., Consoli L., Guarini P., Grison E., Pizzolo F., et al. Low levels of serum paraoxonase activities are characteristic of metabolic syndrome and may influence the metabolic-syndrome-related risk of coronary artery disease. Exp. Diabetes Res. 2012, 2012:231502.
35. Hansel B., Giral P., Nobecourt E., Chantepie S., Bruckert E., Chapman M.J., et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J. Clin. Endocrinol. Metab. 2004, 89:4963-4971.
36. Masana L., Cabre A., Heras M., Amigo N., Correig X., Martinez-Hervas S., et al. Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients. Atherosclerosis 2015, 238:213-219.
37. Nofer J.R., van der G.M., Tolle M., Wolinska I., von Wnuck L.K., Baba H.A., et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest. 2004, 113:569-581.
38. Paragh G., Seres I., Harangi M., Balogh Z., Illyes L., Boda J., et al. The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease. Diabetes Metab. 2003, 29:613-618.
39. Phuntuwate W., Suthisisang C., Koanantakul B., Chaloeiphap P., Mackness B., Mackness M. Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels. Atherosclerosis 2008, 196:122-128.
40. Yesilbursa D., Serdar A., Saltan Y., Serdar Z., Heper Y., Guclu S., et al. The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia. Kardiol. Pol. 2005, 62:526-530.
41. Reriani M.K., Dunlay S.M., Gupta B., West C.P., Rihal C.S., Lerman L.O., et al. Effects of statins on coronary and peripheral endothelial function in humans: a systematic review and meta-analysis of randomized controlled trials. Eur. J. Cardiovasc. Prev. Rehabil. 2011, 18:704-716.
42. Igarashi J., Miyoshi M., Hashimoto T., Kubota Y., Kosaka H. Statins induce S1P(1) receptors and enhance endothelial nitric oxide production in response to high-density lipoproteins. Br. J. Pharmacol. 2007, 150:470-479.
43. Kimura T., Mogi C., Tomura H., Kuwabara A., Im D.S., Sato K., et al. Induction of scavenger receptor class B type I is critical for simvastatin enhancement of high-density lipoprotein-induced anti-inflammatory actions in endothelial cells. J. Immunol. 2008, 181:7332-7340.
44. Higashi Y., Matsuoka H., Umei H., Sugano R., Fujii Y., Soga J., et al. Endothelial function in subjects with isolated low HDL cholesterol: role of nitric oxide and circulating progenitor cells. Am. J. Physiol. Endocrinol. Metab. 2010, 298:E202-E209.
45. Malik J., Melenovsky V., Wichterle D., Haas T., Simek J., Ceska R., et al. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial - FAT). Cardiovasc. Res. 2001, 52:290-298.
46. Wang T.D., Chen W.J., Lin J.W., Cheng C.C., Chen M.F., Lee Y.T. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis 2003, 170:315-323.
47. Evans M., Anderson R.A., Graham J., Ellis G.R., Morris K., Davies S., et al. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation 2000, 101:1773-1779.
48. Avogaro A., Miola M., Favaro A., Gottardo L., Pacini G., Manzato E., et al. Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients. Eur. J. Clin. Investig. 2001, 31:603-609.
49. Ghani R.A., Bin Y.I., Wahab N.A., Zainudin S., Mustafa N., Sukor N., et al. The influence of fenofibrate on lipid profile, endothelial dysfunction, and inflammatory markers in type 2 diabetes mellitus patients with typical and mixed dyslipidemia. J. Clin. Lipidol. 2013, 7:446-453.
50. Kuvin J.T., Ramet M.E., Patel A.R., Pandian N.G., Mendelsohn M.E., Karas R.H. A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am. Heart J. 2002, 144:165-172.
51. Thoenes M., Oguchi A., Nagamia S., Vaccari C.S., Hammoud R., Umpierrez G.E., et al. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome. Int. J. Clin. Pract. 2007, 61:1942-1948.
52. Benjo A.M., Maranhao R.C., Coimbra S.R., Andrade A.C., Favarato D., Molina M.S., et al. Accumulation of chylomicron remnants and impaired vascular reactivity occur in subjects with isolated low HDL cholesterol: effects of niacin treatment. Atherosclerosis 2006, 187:116-122.